4-{[6-(6-fluoropyridin-3-yl)quinazolin-2-yl]amino}-N-(2-methoxyethyl)benzamide | 1032573-72-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-{[6-(6-fluoropyridin-3-yl)quinazolin-2-yl]amino}-N-(2-methoxyethyl)benzamide
• 英文别名: 4-[[6-(6-fluoropyridin-3-yl)quinazolin-2-yl]amino]-N-(2-methoxyethyl)benzamide
• CAS: 1032573-72-0
• 化学式: C₂₃H₂₀FN₅O₂
• 分子量: 417.443
• InChiKey: DZNWRPKWTXMVIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  5-溴-2-氟苯甲醛 在 tris-(dibenzylideneacetone)dipalladium(0) 、 四(三苯基膦)钯 、 potassium carbonate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 29.0h， 生成 4-{[6-(6-fluoropyridin-3-yl)quinazolin-2-yl]amino}-N-(2-methoxyethyl)benzamide
  参考文献：
  名称：

  Discovery and Optimization of a Novel Series of Potent Mutant B-Raf^V600E Selective Kinase Inhibitors

  摘要：

  B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf(V600E) kinase activity both in vitro and in vivo. Investigations into the structure-activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and phannacokinetic profile. Compounds selectively inhibited B-Raf(V600E) in vitro and showed preferential antiproliferative activity in mutant B-Raf(V600E) cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-Raf(V600E) A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro.

  DOI：

  10.1021/jm301658d

文献信息

• Discovery and Optimization of a Novel Series of Potent Mutant B-Raf^V600E Selective Kinase Inhibitors
  作者：Melissa M. Vasbinder、Brian Aquila、Martin Augustin、Huawei Chen、Tony Cheung、Donald Cook、Lisa Drew、Benjamin P. Fauber、Steve Glossop、Michael Grondine、Edward Hennessy、Jeffrey Johannes、Stephen Lee、Paul Lyne、Mario Mörtl、Charles Omer、Sangeetha Palakurthi、Timothy Pontz、Jon Read、Li Sha、Minhui Shen、Stefan Steinbacher、Haixia Wang、Allan Wu、Minwei Ye

  DOI：10.1021/jm301658d

  日期：2013.3.14

  B-Raf represents an attractive target for anticancer therapy and the development of small molecule B-Raf inhibitors has delivered new therapies for metastatic melanoma patients. We have discovered a novel class of small molecules that inhibit mutant B-Raf(V600E) kinase activity both in vitro and in vivo. Investigations into the structure-activity relationships of the series are presented along with efforts to improve upon the cellular potency, solubility, and phannacokinetic profile. Compounds selectively inhibited B-Raf(V600E) in vitro and showed preferential antiproliferative activity in mutant B-Raf(V600E) cell lines and exhibited selectivity in a kinase panel against other kinases. Examples from this series inhibit growth of a B-Raf(V600E) A375 xenograft in vivo at a well-tolerated dose. In addition, aminoquinazolines described herein were shown to display pERK elevation in nonmutant B-Raf cell lines in vitro.